Monday, 16 November 2026

OK 432

 OK-432 is the pioneering work of researchers Hamao Okamoto and S. Koshimura.


Source: OK-432 (Picibanil) is derived from inactivated Streptococcus pyogenes.

 Dual-Action: It acts as both a powerful activator of both native and adaptive immunity (a "biological response modifier") and a potent local sclerosant (causing localized tissue fusion/fibrosis).

 Proof: It is a clinically proven, safe, and effective treatment for specific lymphatic malformations and various cancer types.

 

                                                                               Snapshot


 

 

 

 

  

No comments:

Post a Comment